XBiotech announces Seth Forman to chair second Phase 2 study of bermekimab
XBiotech announces that Seth Forman, M.D., will Chair the Company's upcoming randomized, double-blind, placebo controlled Phase 2 study in Atopic Dermatitis. This second Phase 2 study of bermekimab to treat moderate to severe AD in adults will build on results of a recently completed randomized study that showed rapid improvement in inflammatory lesions and pruritus. Forman is Board Certified in Dermatology and Dermatopathology. Forman was a principal investigator in XBiotech's recent open label study which demonstrated that weekly treatment with bermekimab resulted in rapid and significant improvement of disease in patients with moderate to severe AD. The following outcomes were demonstrated in the study: After only eight weeks of treatment, patients achieved the following clinically significant results: 75% of patients, EASI 75; 80% of patients, reduction in overall pain greater than or equal to4 points; 75% of patients, a reduction in overall itch greater than or equal to4 points;79% of patients, a reduction in anxiety score greater than or equal to4 point; 75% of patients, a reduction in depression score greater than or equal to4 points. In addition, after only four weeks of treatment, patients treated with bermekimab had already achieved the following: 66% reduction in skin lesions, as measured by the Eczema Area and Severity Index ; 57% reduction in worst itch, as measured by the Numerical Rating Scale for Itch ; 61% reduction in worst pain, as measured by the Numerical Rating Scale for Pain.